

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jordan et al. Confirmation No.: 9124
U.S. Appl. No.: 10/561,153
Filing Date: April 5, 2006
For: COMPOUNDS, COMPOSITIONS, AND METHODS FOR
TREATMENT AND PREVENTION OF ORTHOPOXVIRUS
INFECTIONS AND ASSOCIATED DISEASES
Art Unit: 1626
Examiner: Kristin A. Bianchi

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants respectfully submit this Information Disclosure Statement pursuant to 37 C.F.R. § 1.97 and § 1.98 in order to comply with the duty of disclosure under 37 C.F.R. § 1.56. The references are listed on the attached PTO/SB/08A form.

This Information Disclosure Statement is being mailed after the mailing date of the first Office Action, but before the mailing date of a final action under 37 C.F.R. § 1.113, a notice of allowance under 37 C.F.R. § 1.311, or an action that otherwise closes prosecution in the application.

Applicants respectfully request that the information be expressly considered during the prosecution of this application and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. Applicants further request that a copy of the form, appropriately initialed by the Examiner, be returned to Applicant's attorney.

Please note that the statement made in the Information Disclosure Statement filed on June 25, 2009 regarding **compound 41** is incorrect. Compound 41 was invented by the Applicant and not commercially purchased.

The Director is hereby authorized to charge the \$180.00 fee set forth in 37 C.F.R. §1.17(p) or any fee(s) deemed necessary to Deposit Account No. 50-0540.

Respectfully submitted,

Date: December 16, 2009

/Charles Achkar/
Charles Achkar, Reg. No. 43,311
Ilona Gont, Reg. No. 58,714
Kramer Levin Naftalis & Frankel LLP
1177 Avenue of the Americas
New York, N.Y. 10036
(212) 715-9100 (Telephone)
(212) 715-8000 (Facsimile)
CUSTOMER NO. 31013